Literature DB >> 9600357

hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors.

G Colella1, F Vikhanskaya, A M Codegoni, C Bonazzi, M D'Incalci, M Broggini.   

Abstract

The expression of mismatch repair proteins hMSH2 and hMLH1 was investigated in human ovarian cancer cell lines and in biopsies of ovarian carcinomas obtained from 20 patients undergoing surgical operation. By Western blotting analysis hMSH2 protein was detected in all the tumor samples analyzed and in eight out of nine human ovarian cancer cell lines, while hMLH1 was undetectable in four out of 20 ovarian tumors and in five out of nine human ovarian cancer cell lines analyzed. The possible presence of frameshift mutations in the BAX gene, which contains a sequence of eight contiguous guanines in its third exon, was tested in all the samples. All the cell lines presented the normal alleles for the BAX gene while only in one of the tumor samples a heterozygous frameshift mutation was found. The frameshift mutation was associated to a low, almost undetectable, level of BAX protein which was instead present at much higher levels in all the other samples investigated. The results indicate that frameshift mutations in the BAX gene, possibly arising as a consequence of microsatellite instability (detectable in these tumors), is detectable in human ovarian cancer although quantitatively it does not appear to be a major determinant of the low apoptotic response to chemotherapy observed in ovarian cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600357     DOI: 10.1093/carcin/19.4.691

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  3 in total

1.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Authors:  Emily N Manderson; Anne-Marie Mes-Masson; Jaroslav Novak; Peter D Lee; Diane Provencher; Thomas J Hudson; Patricia N Tonin
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

2.  Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.

Authors:  S Dholariya; R Mir; M Zuberi; P Yadav; G Gandhi; N Khurana; A Saxena; P C Ray
Journal:  Clin Transl Oncol       Date:  2015-07-25       Impact factor: 3.405

3.  Mismatch repair and treatment resistance in ovarian cancer.

Authors:  Jozien Helleman; Iris L van Staveren; Winand N M Dinjens; Patricia F van Kuijk; Kirsten Ritstier; Patricia C Ewing; Maria E L van der Burg; Gerrit Stoter; Els M J J Berns
Journal:  BMC Cancer       Date:  2006-07-31       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.